Evidence map›Paper›PMID 36920530›Full record

ArticleUrolithiasis2023

Simple, fast and inexpensive quantification of glycolate in the urine of patients with primary hyperoxaluria type 1.

Thomas Boehm, Cristina Martin-Higueras, Eva Friesser, Clara Zitta, Silvia Wallner, Adam Walli, Katarina Kovacevic, Holger Hubmann, Kristaps Klavins, Peter Macheroux and 2 more

Open access · hybridFull text read
In one paragraph

Article in Urolithiasis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Thomas BoehmDepartment of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.boehm@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-8294-0797
Cristina Martin-HiguerasGerman Hyperoxaluria Center, Bonn, Germany.
Eva FriesserInstitute of Biochemistry, Graz University of Technology, Graz, Austria.
Clara ZittaInstitute of Biochemistry, Graz University of Technology, Graz, Austria.
Silvia WallnerInstitute of Biochemistry, Graz University of Technology, Graz, Austria.
Adam WalliLaboratory Dr. Wisplinghoff, Forensic and Clinical Toxicology, Cologne, Germany.
Katarina KovacevicDepartment of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Holger HubmannDepartment of Paediatrics and Adolescent Medicine, Division of General Paediatrics, Medical University of Graz, Graz, Austria.
Kristaps KlavinsRudolfs Cimdins Riga Biomaterials Innovations and Development Centre, Institute of General Chemical Engineering, Faculty of Materials Science and Applied Chemistry, Riga Technical University, Riga, Latvia.
Peter MacherouxInstitute of Biochemistry, Graz University of Technology, Graz, Austria.
Bernd HoppeGerman Hyperoxaluria Center, Bonn, Germany.
Bernd JilmaDepartment of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Graz University of Technology · ATMedical University of Vienna · ATLaboratory Dr. Wisplinghoff · DEMedical University of Graz · ATRiga Technical University · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In primary hyperoxaluria type 1 excessive endogenous production of oxalate and glycolate leads to increased urinary excretion of these metabolites. Although genetic testing is the most definitive and preferred diagnostic method, quantification of these metabolites is important for the diagnosis and evaluation of potential therapeutic interventions. Current metabolite quantification methods use laborious, technically highly complex and expensive liquid, gas or ion chromatography tandem mass spectrometry, which are available only in selected laboratories worldwide. Incubation of ortho-aminobenzaldehyde (oABA) with glyoxylate generated from glycolate using recombinant mouse glycolate oxidase (GO) and glycine leads to the formation of a stable dihydroquinazoline double aromatic ring chromophore with specific peak absorption at 440 nm. The urinary limit of detection and estimated limit of quantification derived from eight standard curves were 14.3 and 28.7 µmol glycolate per mmol creatinine, respectively. High concentrations of oxalate, lactate and L-glycerate do not interfere in this assay format. The correlation coefficient between the absorption and an ion chromatography tandem mass spectrometry method is 93% with a p value < 0.00001. The Bland-Altmann plot indicates acceptable agreement between the two methods. The glycolate quantification method using conversion of glycolate via recombinant mouse GO and fusion of oABA and glycine with glyoxylate is fast, simple, robust and inexpensive. Furthermore this method might be readily implemented into routine clinical diagnostic laboratories for glycolate measurements in primary hyperoxaluria type 1.

Indexed as

HyperoxaluriaHyperoxaluria, PrimaryAnimalsGlycineGlycolatesGlyoxylatesMiceOxalatesGlycineGlycolatesglycolic acidGlyoxylatesglyoxylic acidOxalatesGlycolateGlyoxylateOrtho-aminobenzaldehydePrimary hyperoxaluria type 1Recombinant glycolate oxidase

Identifiers

PMID36920530
PMCPMC10017573
OpenAlexW4324311357

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read59
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.